Sharaf Karim Perdawood1, Jens Kroeigaard2, Marianne Eriksen2, Pauli Mortensen2. 1. Department of Gastrointestinal Surgery, Slagelse Hospital, Faelledvej 11, 4200, Slagelse, Denmark. sharaf73@hotmail.com. 2. Department of Gastrointestinal Surgery, Slagelse Hospital, Faelledvej 11, 4200, Slagelse, Denmark.
Abstract
OBJECTIVE: To describe outcomes after transanal total mesorectal excision (TaTME) 5 years from implementation at a large-volume colorectal unit, including local recurrence, distant metastasis, and survival. BACKGROUND: Transanal total mesorectal excision (TaTME) is a relatively new procedure for mid- and low-rectal cancer, with well-documented safety and feasibility. However, data on long-term results are limited. METHODS: This study was based on a prospective data collection via a maintained database in a large colorectal unit. The database included patients who underwent TaTME from December 2013 through July 2019. We have updated the database through a review of patient charts, including radiology and pathology reports. Data collection included operative details, intraoperative findings, postoperative complications, pathologic results, and oncologic results. RESULTS: During the study period, two hundred patients underwent TaTME in the study period (men = 147). The mean BMI was 26.7%, and the mean tumor height from the anal verge was 7.86 cm. Neoadjuvant treatment was given to 22% of patients. Anastomotic leakage occurred in 9.3% of patients, and the overall rate of postoperative complications was 24.5%. The TME specimen was incomplete in 11% of patients, and the CRM was positive in 5.5% of patients. Local recurrence (LR) occurred in seven patients with a follow-up of at least 2 years (4.7%). Distant metastasis (DM) occurred in 12% of patients. The overall survival was 90% and disease-free survival was 81%. The operating time was reduced in the later period of our experience. CONCLUSIONS: This study showed that TaTME is feasible, safe, and had acceptable short-term outcomes and an acceptable rate of LR. The study included, however, one group that was non-randomized, and the follow-up was not long enough for most patients. Studies with longer follow-up data are awaited.
OBJECTIVE: To describe outcomes after transanal total mesorectal excision (TaTME) 5 years from implementation at a large-volume colorectal unit, including local recurrence, distant metastasis, and survival. BACKGROUND: Transanal total mesorectal excision (TaTME) is a relatively new procedure for mid- and low-rectal cancer, with well-documented safety and feasibility. However, data on long-term results are limited. METHODS: This study was based on a prospective data collection via a maintained database in a large colorectal unit. The database included patients who underwent TaTME from December 2013 through July 2019. We have updated the database through a review of patient charts, including radiology and pathology reports. Data collection included operative details, intraoperative findings, postoperative complications, pathologic results, and oncologic results. RESULTS: During the study period, two hundred patients underwent TaTME in the study period (men = 147). The mean BMI was 26.7%, and the mean tumor height from the anal verge was 7.86 cm. Neoadjuvant treatment was given to 22% of patients. Anastomotic leakage occurred in 9.3% of patients, and the overall rate of postoperative complications was 24.5%. The TME specimen was incomplete in 11% of patients, and the CRM was positive in 5.5% of patients. Local recurrence (LR) occurred in seven patients with a follow-up of at least 2 years (4.7%). Distant metastasis (DM) occurred in 12% of patients. The overall survival was 90% and disease-free survival was 81%. The operating time was reduced in the later period of our experience. CONCLUSIONS: This study showed that TaTME is feasible, safe, and had acceptable short-term outcomes and an acceptable rate of LR. The study included, however, one group that was non-randomized, and the follow-up was not long enough for most patients. Studies with longer follow-up data are awaited.
Entities:
Keywords:
Oncologic results; Rectal cancer surgery; TaTME; Total mesorectal excision
Authors: Iris D Nagtegaal; Cornelis J H van de Velde; Erik van der Worp; Ellen Kapiteijn; Phil Quirke; J Han J M van Krieken Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: James Fleshman; Megan Branda; Daniel J Sargent; Anne Marie Boller; Virgilio George; Maher Abbas; Walter R Peters; Dipen Maun; George Chang; Alan Herline; Alessandro Fichera; Matthew Mutch; Steven Wexner; Mark Whiteford; John Marks; Elisa Birnbaum; David Margolin; David Larson; Peter Marcello; Mitchell Posner; Thomas Read; John Monson; Sherry M Wren; Peter W T Pisters; Heidi Nelson Journal: JAMA Date: 2015-10-06 Impact factor: 56.272
Authors: Phil Quirke; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Jean Couture; Chris O'Callaghan; Arthur Sun Myint; Eric Bessell; Lindsay C Thompson; Mahesh Parmar; Richard J Stephens; David Sebag-Montefiore Journal: Lancet Date: 2009-03-07 Impact factor: 79.321
Authors: Ivy H Gardner; Katherine A Kelley; Walaa F Abdelmoaty; Ahmed Sharata; Amanda V Hayman; Mark H Whiteford Journal: Surg Endosc Date: 2021-01-08 Impact factor: 4.584
Authors: Antonio Caycedo-Marulanda; Lawrence Lee; Sami A Chadi; Chris P Verschoor; Jordan Crosina; Shady Ashamalla; Carl J Brown Journal: JAMA Netw Open Date: 2021-02-01
Authors: Carolina González-Abós; F Borja de Lacy; Yoelimar Guzmán; Sara T Nogueira; Ana Otero-Piñeiro; Raúl Almenara; Antonio M Lacy Journal: Surg Endosc Date: 2021-01-04 Impact factor: 4.584